Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index

Yi Yang Chen, Cih En Huang, Fu Wen Liang, Chang Hsien Lu, Pin Tsung Chen, Kuan Der Lee, Chih Cheng Chen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Patients with hepatitis C virus (HCV) infection have been associated with development of diffuse large B-cell lymphoma (DLBCL), yet its impact on several clinical aspects, including phenotypic characteristics and treatment-related toxicities as well as survival outcome after rituximab-based immunochemotherapy, remains controversial. Methods: To elucidate the characteristics of HCV-positive DLBCL in the context of a new prognostic model, the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI), we retrospectively analyzed DLBCL patients diagnosed and treated with immunochemotherapy at our institute during the last decade. Results: In all, HCV infection was identified in 22 (17.7%) of 124 DLBCL patients. Except for being more likely to present with an advanced stage of disease, patients with HCV infection were phenotypically indistinguishable from HCV-negative cases. Multivariate analysis showed 3 factors independently predicted a dismal overall survival (OS) outcome: lower albumin level (<3. g/dL vs. ≫3. g/dL, p<. 0.001; HR. =. 13.21, 95% CI. =. 2.69-64.98, p=. 0.001), presence of HCV infection (vs. HCV-negative; HR. =. 9.75, 95% CI. =. 1.97-48.34, p=. 0.005), and poor NCCN-IPI risk (high-intermediate or high vs. low-intermediate or low; HR. =. 5.56, 95% CI. =. 1.17-26.55, p=. 0.031). Conclusions: Our study has demonstrated that HCV infection status and low serum albumin level add important prognostic values to the newly proposed NCCN-IPI model for patients with DLBCL.

Original languageEnglish
Pages (from-to)382-387
Number of pages6
JournalCancer Epidemiology
Volume39
Issue number3
DOIs
Publication statusPublished - Jun 1 2015
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Virus Diseases
Hepacivirus
Neoplasms
Survival
Serum Albumin
Albumins
Multivariate Analysis

Keywords

  • Albumin
  • Diffuse large B-cell lymphoma
  • Hepatitis C
  • NCCN-IPI
  • Prognosis
  • Rituximab

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Cancer Research

Cite this

Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index. / Chen, Yi Yang; Huang, Cih En; Liang, Fu Wen; Lu, Chang Hsien; Chen, Pin Tsung; Lee, Kuan Der; Chen, Chih Cheng.

In: Cancer Epidemiology, Vol. 39, No. 3, 01.06.2015, p. 382-387.

Research output: Contribution to journalArticle

Chen, Yi Yang ; Huang, Cih En ; Liang, Fu Wen ; Lu, Chang Hsien ; Chen, Pin Tsung ; Lee, Kuan Der ; Chen, Chih Cheng. / Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index. In: Cancer Epidemiology. 2015 ; Vol. 39, No. 3. pp. 382-387.
@article{0b8cdc5e119340768eecf2db08dad13c,
title = "Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index",
abstract = "Objective: Patients with hepatitis C virus (HCV) infection have been associated with development of diffuse large B-cell lymphoma (DLBCL), yet its impact on several clinical aspects, including phenotypic characteristics and treatment-related toxicities as well as survival outcome after rituximab-based immunochemotherapy, remains controversial. Methods: To elucidate the characteristics of HCV-positive DLBCL in the context of a new prognostic model, the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI), we retrospectively analyzed DLBCL patients diagnosed and treated with immunochemotherapy at our institute during the last decade. Results: In all, HCV infection was identified in 22 (17.7{\%}) of 124 DLBCL patients. Except for being more likely to present with an advanced stage of disease, patients with HCV infection were phenotypically indistinguishable from HCV-negative cases. Multivariate analysis showed 3 factors independently predicted a dismal overall survival (OS) outcome: lower albumin level (<3. g/dL vs. ≫3. g/dL, p<. 0.001; HR. =. 13.21, 95{\%} CI. =. 2.69-64.98, p=. 0.001), presence of HCV infection (vs. HCV-negative; HR. =. 9.75, 95{\%} CI. =. 1.97-48.34, p=. 0.005), and poor NCCN-IPI risk (high-intermediate or high vs. low-intermediate or low; HR. =. 5.56, 95{\%} CI. =. 1.17-26.55, p=. 0.031). Conclusions: Our study has demonstrated that HCV infection status and low serum albumin level add important prognostic values to the newly proposed NCCN-IPI model for patients with DLBCL.",
keywords = "Albumin, Diffuse large B-cell lymphoma, Hepatitis C, NCCN-IPI, Prognosis, Rituximab",
author = "Chen, {Yi Yang} and Huang, {Cih En} and Liang, {Fu Wen} and Lu, {Chang Hsien} and Chen, {Pin Tsung} and Lee, {Kuan Der} and Chen, {Chih Cheng}",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.canep.2015.04.004",
language = "English",
volume = "39",
pages = "382--387",
journal = "Cancer Epidemiology",
issn = "1877-7821",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index

AU - Chen, Yi Yang

AU - Huang, Cih En

AU - Liang, Fu Wen

AU - Lu, Chang Hsien

AU - Chen, Pin Tsung

AU - Lee, Kuan Der

AU - Chen, Chih Cheng

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Objective: Patients with hepatitis C virus (HCV) infection have been associated with development of diffuse large B-cell lymphoma (DLBCL), yet its impact on several clinical aspects, including phenotypic characteristics and treatment-related toxicities as well as survival outcome after rituximab-based immunochemotherapy, remains controversial. Methods: To elucidate the characteristics of HCV-positive DLBCL in the context of a new prognostic model, the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI), we retrospectively analyzed DLBCL patients diagnosed and treated with immunochemotherapy at our institute during the last decade. Results: In all, HCV infection was identified in 22 (17.7%) of 124 DLBCL patients. Except for being more likely to present with an advanced stage of disease, patients with HCV infection were phenotypically indistinguishable from HCV-negative cases. Multivariate analysis showed 3 factors independently predicted a dismal overall survival (OS) outcome: lower albumin level (<3. g/dL vs. ≫3. g/dL, p<. 0.001; HR. =. 13.21, 95% CI. =. 2.69-64.98, p=. 0.001), presence of HCV infection (vs. HCV-negative; HR. =. 9.75, 95% CI. =. 1.97-48.34, p=. 0.005), and poor NCCN-IPI risk (high-intermediate or high vs. low-intermediate or low; HR. =. 5.56, 95% CI. =. 1.17-26.55, p=. 0.031). Conclusions: Our study has demonstrated that HCV infection status and low serum albumin level add important prognostic values to the newly proposed NCCN-IPI model for patients with DLBCL.

AB - Objective: Patients with hepatitis C virus (HCV) infection have been associated with development of diffuse large B-cell lymphoma (DLBCL), yet its impact on several clinical aspects, including phenotypic characteristics and treatment-related toxicities as well as survival outcome after rituximab-based immunochemotherapy, remains controversial. Methods: To elucidate the characteristics of HCV-positive DLBCL in the context of a new prognostic model, the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI), we retrospectively analyzed DLBCL patients diagnosed and treated with immunochemotherapy at our institute during the last decade. Results: In all, HCV infection was identified in 22 (17.7%) of 124 DLBCL patients. Except for being more likely to present with an advanced stage of disease, patients with HCV infection were phenotypically indistinguishable from HCV-negative cases. Multivariate analysis showed 3 factors independently predicted a dismal overall survival (OS) outcome: lower albumin level (<3. g/dL vs. ≫3. g/dL, p<. 0.001; HR. =. 13.21, 95% CI. =. 2.69-64.98, p=. 0.001), presence of HCV infection (vs. HCV-negative; HR. =. 9.75, 95% CI. =. 1.97-48.34, p=. 0.005), and poor NCCN-IPI risk (high-intermediate or high vs. low-intermediate or low; HR. =. 5.56, 95% CI. =. 1.17-26.55, p=. 0.031). Conclusions: Our study has demonstrated that HCV infection status and low serum albumin level add important prognostic values to the newly proposed NCCN-IPI model for patients with DLBCL.

KW - Albumin

KW - Diffuse large B-cell lymphoma

KW - Hepatitis C

KW - NCCN-IPI

KW - Prognosis

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84929943737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929943737&partnerID=8YFLogxK

U2 - 10.1016/j.canep.2015.04.004

DO - 10.1016/j.canep.2015.04.004

M3 - Article

VL - 39

SP - 382

EP - 387

JO - Cancer Epidemiology

JF - Cancer Epidemiology

SN - 1877-7821

IS - 3

ER -